Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Quality assurance in specialized headache units in Spain: an observational prospective study.

PMID: 31238877
Journal: JOURNAL OF HEADACHE AND PAIN
Year: 2019
Reference: J Headache Pain. 2019 Jun 25;20(1):73. doi: 10.1186/s10194-019-1020-1.
Impact factor:
Publication type: Paper in international publication
Authors: Balseiro-Gomez, Jose; Guerrero-Peral, Angel L; Ignacio, Emilio; Latorre-Gonzalez, German; Layos-Romero, Almudena; Lucas, Cesar; Martinez-Garcia, Alba; Mira, Jose J; Pascual, Julio; Porta-Etessam, Jesus et al.
DOI: 10.1186/s10194-019-1020-1

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

PMID: 31394303
Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Year: 2019
Reference: J Pharm Biomed Anal. 2019 Nov 30;176:112798. doi: 10.1016/j.jpba.2019.112798. Epub 2019 Aug 1.
Impact factor: 2.983
Publication type: Paper in international publication
Authors: Ruiz-Pons, Monica, Canedo, Elvira, Barba Romero, Miguel Angel, Garcia-Jimenez, M feminine Concepcion, Aldamiz-Echevarria, Luis, Del Toro, Mireia, Gil, David, Blasco, Javier, Andrade, Fernando, Vitoria, Isidro et al.
DOI: 10.1016/j.jpba.2019.112798

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

PMID: 31394303
Journal: JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Year: 2019
Reference: J Pharm Biomed Anal. 2019 Nov 30;176:112798. doi: 10.1016/j.jpba.2019.112798. Epub 2019 Aug 1.
Impact factor:
Publication type: Paper in international publication
Authors: Aldamiz-Echevarria, Luis; Almeida Campos, Teresa; Andrade, Fernando; Barba Romero, Miguel Angel; Blasco, Javier; Canedo, Elvira; Ceberio, Leticia; Correcher, Patricia; de Las Heras, Javier; Del Toro, Mireia et al.
DOI: 10.1016/j.jpba.2019.112798

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

PMID: 31763460
Journal: Surgery journal (New York, N.Y.)
Year: 2019
Reference: Surg J (N Y). 2019 Nov 21;5(4):e184-e187. doi: 10.1055/s-0039-3400278. eCollection 2019 Oct.
Impact factor: 0
Publication type: Paper in international publication
Authors: Seijas, Roberto, Catala, Jordi, Cepas, Miguel Angel, Sallent, Andrea, Ares, Oscar, Barastegui, David et al.
DOI: 10.1055/s-0039-3400278

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

PMID: 31763460
Journal: Surgery journal (New York, N.Y.)
Year: 2019
Reference: Surg J (N Y). 2019 Nov 21;5(4):e184-e187. doi: 10.1055/s-0039-3400278. eCollection 2019 Oct.
Impact factor:
Publication type: Paper in international publication
Authors: Ares, Oscar; Barastegui, David; Catala, Jordi; Cepas, Miguel Angel; Sallent, Andrea; Seijas, Roberto et al.
DOI: 10.1055/s-0039-3400278

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

PMID: 29908339
Journal: Journal of Minimally Invasive Gynecology
Year: 2019
Reference: J Minim Invasive Gynecol. 2019 Mar - Apr;26(3):492-500. doi: 10.1016/j.jmig.2018.06.007. Epub 2018 Jun 13.
Impact factor: 2.414
Publication type: Paper in international publication
Authors: Gil-Moreno, Antonio, Carbonell-Socias, Melchor, Salicru, Sabina, Centeno-Mediavilla, Cristina, Franco-Camps, Silvia, Colas, Eva, Oaknin, Ana, Perez-Benavente, Assumpcio, Diaz-Feijoo, Berta et al.
DOI: 10.1016/j.jmig.2018.06.007

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

PMID: 29908339
Journal: Journal of Minimally Invasive Gynecology
Year: 2019
Reference: J Minim Invasive Gynecol. 2019 Mar - Apr;26(3):492-500. doi: 10.1016/j.jmig.2018.06.007. Epub 2018 Jun 13.
Impact factor:
Publication type: Paper in international publication
Authors: Carbonell-Socias, Melchor; Centeno-Mediavilla, Cristina; Colas, Eva; Diaz-Feijoo, Berta; Franco-Camps, Silvia; Gil-Moreno, Antonio; Oaknin, Ana; Perez-Benavente, Assumpcio; Salicru, Sabina et al.
DOI: 10.1016/j.jmig.2018.06.007

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

PMID: 31035085
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Jun;114:36-46. doi: 10.1016/j.ejca.2019.03.018. Epub 2019 Apr 28.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: de Rojas, Teresa, Clementel, Enrico, Giralt, Jordi, Cruz, Ofelia, Boterberg, Tom, Kortmann, Rolf-Dieter, Gaze, Mark N, Moreno, Lucas, Janssens, Geert O et al.
DOI: 10.1016/j.ejca.2019.03.018

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

PMID: 31035085
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Jun;114:36-46. doi: 10.1016/j.ejca.2019.03.018. Epub 2019 Apr 28.
Impact factor:
Publication type: Paper in international publication
Authors: Boterberg, Tom; Clementel, Enrico; Cruz, Ofelia; de Rojas, Teresa; Gaze, Mark N; Giralt, Jordi; Janssens, Geert O; Kortmann, Rolf-Dieter; Moreno, Lucas et al.
DOI: 10.1016/j.ejca.2019.03.018

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

PMID: 30612558
Journal: BMC CANCER
Year: 2019
Reference: BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.
Impact factor: 2.933
Publication type: Paper in international publication
Authors: Heidenreich, Axel, Gillessen, Silke, Heinrich, Daniel, Keizman, Daniel, O'Sullivan, Joe M, Carles, Joan, Wirth, Manfred, Miller, Kurt, Reeves, John, Seger, Monica et al.
DOI: 10.1186/s12885-018-5203-y

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

PMID: 30612558
Journal: BMC CANCER
Year: 2019
Reference: BMC Cancer. 2019 Jan 7;19(1):12. doi: 10.1186/s12885-018-5203-y.
Impact factor:
Publication type: Paper in international publication
Authors: Carles, Joan; Gillessen, Silke; Heidenreich, Axel; Heinrich, Daniel; Keizman, Daniel; Miller, Kurt; Nilsson, Sten; O'Sullivan, Joe M; Reeves, John; Saad, Fred et al.
DOI: 10.1186/s12885-018-5203-y

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

PMID: 31301962
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.
Impact factor: 35.386
Publication type: Paper in international publication
Authors: Arkenau, Hendrik-Tobias, Santana-Davila, Rafael, Calvo, Emiliano, Paz-Ares, Luis, Cassier, Philippe A, Bendell, Johanna, Penel, Nicolas, Krebs, Matthew G, Martin-Liberal, Juan, Isambert, Nicolas et al.
DOI: 10.1016/S1470-2045(19)30458-9

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

PMID: 31301962
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Aug;20(8):1109-1123. doi: 10.1016/S1470-2045(19)30458-9. Epub 2019 Jul 10.
Impact factor:
Publication type: Paper in international publication
Authors: Arkenau, Hendrik-Tobias; Bendell, Johanna; Calvo, Emiliano; Cassier, Philippe A; Chau, Ian; Cultrera, Jennifer; Ferry, David; Fuchs, Charles S; Gao, Ling; Herbst, Roy S et al.
DOI: 10.1016/S1470-2045(19)30458-9

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

PMID: 30718072
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1.
Impact factor: 35.386
Publication type: Paper in international publication
Authors: Prausova, Jana, Van Cutsem, Eric, Ilson, David H, Alsina, Maria, Chau, Ian, Lacy, Jill, Ducreux, Michel, Mendez, Guillermo Ariel, Alavez, Alejandro Molina, Takahari, Daisuke et al.
DOI: 10.1016/S1470-2045(18)30791-5

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

PMID: 30718072
Journal: LANCET ONCOLOGY
Year: 2019
Reference: Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1.
Impact factor:
Publication type: Paper in international publication
Authors: Acs, Peter Istvan; Al-Batran, Salah-Eddin; Alavez, Alejandro Molina; Alcindor, Thierry; Alsina, Maria; Aprile, Giuseppe; Asmis, Timothy R; Ayala, Hubert; Bajaj, Madhuri; Barone, Carlo et al.
DOI: 10.1016/S1470-2045(18)30791-5

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

PMID: 30654297
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: Paz-Ares, Luis, Levy, Benjamin P, Giaccone, Giuseppe, Besse, Benjamin, Felip, Enriqueta, Garassino, Marina Chiara, Domine Gomez, Manuel, Garrido, Pilar, Piperdi, Bilal, Ponce-Aix, Santiago et al.
DOI: 10.1016/j.ejca.2018.11.028

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

PMID: 30654297
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Feb;108:120-128. doi: 10.1016/j.ejca.2018.11.028. Epub 2019 Jan 14.
Impact factor:
Publication type: Paper in international publication
Authors: Besse, Benjamin; Domine Gomez, Manuel; Fandi, Abderrahim; Felip, Enriqueta; Garassino, Marina Chiara; Garrido, Pilar; Giaccone, Giuseppe; Levy, Benjamin P; MacBeth, Kyle J; Menezes, Daniel et al.
DOI: 10.1016/j.ejca.2018.11.028

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

PMID: 30890552
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19.
Impact factor: 8.911
Publication type: Paper in international publication
Authors: Goldschmidt, Hartmut, Brighton, Timothy A, Khot, Amit, Harrison, Simon J, Ghez, David, Weiss, Brendan M, Kirsch, Andreas, Magen, Hila, Gironella, Mercedes, Oriol, Albert et al.
DOI: 10.1158/1078-0432.CCR-18-3470

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

PMID: 30890552
Journal: CLINICAL CANCER RESEARCH
Year: 2019
Reference: Clin Cancer Res. 2019 Jul 1;25(13):3772-3775. doi: 10.1158/1078-0432.CCR-18-3470. Epub 2019 Mar 19.
Impact factor:
Publication type: Paper in international publication
Authors: Bandekhar, Rajesh; Brighton, Timothy A; Ghez, David; Gironella, Mercedes; Goldschmidt, Hartmut; Guilfoyle, Mary; Harrison, Simon J; Hu, Peter; Khot, Amit; Kirsch, Andreas et al.
DOI: 10.1158/1078-0432.CCR-18-3470

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

PMID: 32085197
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4.
Impact factor: 14.196
Publication type: Letter or abstract
Authors: Maurel, J, Taberner, M, Rodriguez-Salas, N, Aparicio, J, Virgili, A, Capdevila, J, Munoz Boza, F, Alvarez, R, Bosch, C, Camara, J et al.
DOI: 10.1093/annonc/mdz155.190

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

PMID: 32085197
Journal: ANNALS OF ONCOLOGY
Year: 2019
Reference: Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4.
Impact factor:
Publication type: Letter or abstract
Authors: Alvarez, R; Aparicio, J; Bosch, C; Camara, J; Capdevila, J; Fernandez-Martos, C; Fernandez-Plana, J; Gallego, J; Gallego, R; Hernandez-Yague, X et al.
DOI: 10.1093/annonc/mdz155.190

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

PMID: 30975923
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.
Impact factor: 5.252
Publication type: Paper in international publication
Authors: Lopez-Chavez, Ariel, Doebele, Robert C, Modiano, Manuel R, Jackman, David Michael, Baggstrom, Maria Quintos, Atmaca, Akin, Felip, Enriqueta, Provencio, Mariano, Cobo, Manuel, Adiwijaya, Bambang et al.
DOI: 10.1634/theoncologist.2018-0695

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

PMID: 30975923
Journal: ONCOLOGIST
Year: 2019
Reference: Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.
Impact factor:
Publication type: Paper in international publication
Authors: Adiwijaya, Bambang; Andreas, Karen; Atmaca, Akin; Baggstrom, Maria Quintos; Cho, Byoung Chul; Cobo, Manuel; Doebele, Robert C; Felip, Enriqueta; Gray, Jhanelle Elaine; Harb, Wael A et al.
DOI: 10.1634/theoncologist.2018-0695

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

PMID: 30901302
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Turgut, Mehmet, Jurczak, Wojciech, Cheung, Matthew C, Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Duhrsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram et al.
DOI: 10.1200/JCO.18.02403

Publications

Publications searcher

Quality assurance in specialized headache units in Spain: an observational prospective study.

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

Quantification of urinary derivatives of Phenylbutyric and Benzoic acids by LC-MS/MS as treatment compliance biomarkers in Urea Cycle disorders.

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

Radiation Exposure from Fluoroscopy during Hip Arthroscopy.

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

Radical Hysterectomy: Efficacy and Safety in the Dawn of Minimally Invasive Techniques.

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

Radiotherapy practice for paediatric brain tumours across Europe and quality assurance initiatives: Current situation, international survey and future perspectives.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND).

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Patronage:

Collaborating:

Accreditations: